Cargando…

Gene therapy for carcinoma of the breast: Genetic toxins

Gene therapy was initially envisaged as a potential treatment for genetically inherited, monogenic disorders. The applications of gene therapy have now become wider, however, and include cardiovascular diseases, vaccination and cancers in which conventional therapies have failed. With regard to onco...

Descripción completa

Detalles Bibliográficos
Autores principales: Vassaux, Georges, Lemoine, Nick R
Formato: Texto
Lenguaje:English
Publicado: 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC521210/
https://www.ncbi.nlm.nih.gov/pubmed/11250689
http://dx.doi.org/10.1186/bcr25
_version_ 1782121834611736576
author Vassaux, Georges
Lemoine, Nick R
author_facet Vassaux, Georges
Lemoine, Nick R
author_sort Vassaux, Georges
collection PubMed
description Gene therapy was initially envisaged as a potential treatment for genetically inherited, monogenic disorders. The applications of gene therapy have now become wider, however, and include cardiovascular diseases, vaccination and cancers in which conventional therapies have failed. With regard to oncology, various gene therapy approaches have been developed. Among them, the use of genetic toxins to kill cancer cells selectively is emerging. Two different types of genetic toxins have been developed so far: the metabolic toxins and the dominant-negative class of toxins. This review describes these two different approaches, and discusses their potential applications in cancer gene therapy.
format Text
id pubmed-521210
institution National Center for Biotechnology Information
language English
publishDate 2000
record_format MEDLINE/PubMed
spelling pubmed-5212102004-10-04 Gene therapy for carcinoma of the breast: Genetic toxins Vassaux, Georges Lemoine, Nick R Breast Cancer Res Review Gene therapy was initially envisaged as a potential treatment for genetically inherited, monogenic disorders. The applications of gene therapy have now become wider, however, and include cardiovascular diseases, vaccination and cancers in which conventional therapies have failed. With regard to oncology, various gene therapy approaches have been developed. Among them, the use of genetic toxins to kill cancer cells selectively is emerging. Two different types of genetic toxins have been developed so far: the metabolic toxins and the dominant-negative class of toxins. This review describes these two different approaches, and discusses their potential applications in cancer gene therapy. 2000 1999-12-17 /pmc/articles/PMC521210/ /pubmed/11250689 http://dx.doi.org/10.1186/bcr25 Text en Copyright © 1999 Current Science Ltd
spellingShingle Review
Vassaux, Georges
Lemoine, Nick R
Gene therapy for carcinoma of the breast: Genetic toxins
title Gene therapy for carcinoma of the breast: Genetic toxins
title_full Gene therapy for carcinoma of the breast: Genetic toxins
title_fullStr Gene therapy for carcinoma of the breast: Genetic toxins
title_full_unstemmed Gene therapy for carcinoma of the breast: Genetic toxins
title_short Gene therapy for carcinoma of the breast: Genetic toxins
title_sort gene therapy for carcinoma of the breast: genetic toxins
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC521210/
https://www.ncbi.nlm.nih.gov/pubmed/11250689
http://dx.doi.org/10.1186/bcr25
work_keys_str_mv AT vassauxgeorges genetherapyforcarcinomaofthebreastgenetictoxins
AT lemoinenickr genetherapyforcarcinomaofthebreastgenetictoxins